Trial · NCT06357806
The Treatment of PD-1 Antibody Combined With Peg-IFNα in NAs-suppressed CHB Patients
NCT06357806, Not applicable, Active not recruiting, Beijing 302 Hospital
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. The Treatment of PD-1 Antibody Combined With Peg-IFNα in NAs-suppressed CHB Patients. Trials, record NCT06357806. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06357806
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- The Treatment of PD-1 Antibody Combined With Peg-IFNα in NAs-suppressed CHB Patients
- NCT number
- NCT06357806
- Status
- Active not recruiting
- Phases
- Not applicable
- Enrollment
- 45 participants, estimated
- Lead sponsor
- Beijing 302 Hospital
- Conditions
- Chronic Hepatitis B
- Interventions
- Sintilimab, Peg-IFNα-2b, NAs
- First posted
- 2024-04-10
- Last updated
- 2026-03-18
Source ClinicalTrials.gov
Registered outcomes8
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | The rate of HBsAg loss at 24 weeks and 48 weeks. | 48 weeks | Evaluate the level of HBsAg at 24 weeks and 48 weeks. |
| Primary | Incidence of treatment-emergent adverse events/serious adverse events | 48 weeks | Evaluate the treatment-emergent adverse events/serious adverse events |
| Secondary | The rate of HBsAg decline > 1log(IU/ml) at 24 weeks and 48 weeks | 48 weeks | Evaluate the level of serum HBsAg at 24 weeks and 48 weeks. |
| Secondary | The rate of HBsAb positive at 24 weeks and 48 weeks. | 48 weeks | Evaluate the level of serum HBsAb at 24 weeks and 48 weeks. |
| Secondary | The concentration of HBcrAg at baseline, 12 weeks, 24 weeks and 48 weeks. | 48 weeks | Evaluate the level of serum HBcrAg at baseline, 12 weeks, 24 weeks and 48 weeks. |
| Secondary | The concentration of pgRNA at baseline, 12 weeks, 24 weeks and 48 weeks. | 48 weeks | Evaluate the level of serum pgRNA at baseline, 12 weeks, 24 weeks and 48 weeks. |
| Secondary | The concentration of anti-HBc at baseline, 12 weeks, 24 weeks and 48 weeks. | 48 weeks | Evaluate the level of serum anti-HBc at baseline, 12 weeks, 24 weeks and 48 weeks. |
| Secondary | Immune response of T cell, B cell, NK cell at baseline, 12 weeks, 24 weeks and 48 weeks. | 48 weeks | Evaluate the frequency and function of T cell, B cell, NK cell (tested by flowcytometry/fluorospot/elispot) |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 40976664 | DERIVED |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06357806
GET https://conductscience.org/api/trials/v1/NCT06357806/registered